SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Conditions: Endometrial Cancer Stage I; Mmr Deficiency; Endometrioid Endometrial Adenocarcinoma; Immune-related Adverse Event Interventions: Drug: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] Sponsors: Queensland Centre for Gynaecological Cancer; GlaxoSmithKline Research& Development Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials